Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted inducement stock options to two new employees. The grants include options to purchase 134,000 shares of common stock at an exercise price of $0.65 per share, matching the closing price on August 1, 2025.
The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), una società biotecnologica in fase clinica specializzata in terapie immuno-oncologiche attivate dai tumori, ha concesso opzioni azionarie come incentivo a due nuovi dipendenti. Le concessioni comprendono opzioni per acquistare 134.000 azioni ordinarie a un prezzo di esercizio di 0,65$ per azione, corrispondente al prezzo di chiusura del 1° agosto 2025.
Le opzioni azionarie hanno una durata di dieci anni con un piano di maturazione del 25% dopo il primo anno e il restante 75% che matura in 36 rate mensili. Queste concessioni sono state effettuate nell'ambito del Piano di Incentivazione Azionaria per Induzione 2022 di Xilio, in conformità con la Regola 5635(c)(4) del Nasdaq.
Xilio Therapeutics (Nasdaq: XLO), una empresa biotecnológica en etapa clínica centrada en terapias inmuno-oncológicas activadas por tumores, ha otorgado opciones sobre acciones como incentivo a dos nuevos empleados. Las concesiones incluyen opciones para comprar 134,000 acciones ordinarias a un precio de ejercicio de $0.65 por acción, que coincide con el precio de cierre del 1 de agosto de 2025.
Las opciones tienen un plazo de diez años con un calendario de adquisición del 25% después del primer año y el 75% restante que se adquiere en 36 cuotas mensuales. Estas concesiones se realizaron bajo el Plan de Incentivos de Acciones por Inducción 2022 de Xilio, conforme a la Regla 5635(c)(4) de Nasdaq.
Xilio Therapeutics (나스닥: XLO)는 종양 활성화 면역항암 치료제에 중점을 둔 임상 단계 생명공학 회사로, 두 명의 신입 직원에게 유인 주식 옵션을 부여했습니다. 이번 부여는 2025년 8월 1일 종가와 동일한 주당 $0.65의 행사 가격으로 134,000주의 보통주를 구매할 수 있는 옵션을 포함합니다.
주식 옵션의 유효 기간은 10년이며, 1년 후 25%가 베스팅 되고 나머지 75%는 36개월에 걸쳐 월별로 베스팅됩니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 Xilio의 2022년 유인 주식 인센티브 계획에 따라 이루어졌습니다.
Xilio Therapeutics (Nasdaq : XLO), une société biotechnologique en phase clinique spécialisée dans les thérapies immuno-oncologiques activées par les tumeurs, a accordé des options d'achat d'actions incitatives à deux nouveaux employés. Ces attributions comprennent des options pour acheter 134 000 actions ordinaires au prix d'exercice de 0,65 $ par action, correspondant au cours de clôture du 1er août 2025.
Les options d'achat ont une durée de dix ans avec un calendrier d'acquisition de 25 % après la première année et les 75 % restants acquis en 36 versements mensuels. Ces attributions ont été effectuées dans le cadre du Plan d'Incitation à l'Attribution d'Actions 2022 de Xilio, conformément à la règle 5635(c)(4) du Nasdaq.
Xilio Therapeutics (Nasdaq: XLO), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf tumoraktivierte Immunonkologie-Therapien, hat zwei neue Mitarbeiter mit Anreiz-Aktienoptionen ausgestattet. Die Zuteilungen umfassen Optionen zum Kauf von 134.000 Stammaktien zu einem Ausübungspreis von 0,65 $ pro Aktie, entsprechend dem Schlusskurs vom 1. August 2025.
Die Aktienoptionen haben eine Laufzeit von zehn Jahren mit einem Vesting-Plan von 25 % nach dem ersten Jahr und den verbleibenden 75 %, die in 36 monatlichen Raten vesten. Diese Zuteilungen erfolgten im Rahmen von Xilios Inducement Stock Incentive Plan 2022 gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective August 1, 2025, the company granted non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
investors@xiliotx.com
Media Contact
Dan Budwick
1AB
dan@1abmedia.com
FAQ
What stock options did Xilio Therapeutics (XLO) grant to new employees in August 2025?
What is the vesting schedule for Xilio Therapeutics' (XLO) August 2025 stock option grants?
What is the exercise price of Xilio Therapeutics' (XLO) August 2025 inducement stock options?
How long is the term of Xilio Therapeutics' (XLO) August 2025 inducement stock options?
